Study Drug vs Placebo as an add on” treatment for Severe Community-Acquired Pneumonia.

Phase 1

Recruiting

• Conditions: Severe Community-Acquired Pneumonia; MedDRA version: 20.1Level: LLTClassification code: 10010120Term: Community acquired pneumonia Class: 10021881; Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

• Registration Number: CTIS2023-505985-28-01
• Lead Sponsor: Aptarion Biotech AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-17
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

At Screening, Randomisation and prior to administration of first dose; community-acquired pneumonia according to local guidelines. Community-acquired pneumonia may be confirmed or suspected to be of bacterial or viral origin., For female participants of childbearing potential, agreement to use dual methods of contraception until Day 60., For male participants with female partners of childbearing potential, agreement to use barrier method of contraception until Day 60 and to refrain from donating sperm during the study and for 3 months after the last infusion., At Screening, Randomisation and prior to administration of first dose; admitted to an Intensive Care Unit (or similar unit) defined as any hospital facility with intensive and specialised medical and nursing care, with capacity for monitoring, and physiological organ support to sustain life during a period of life-threatening organ system insufficiency., At Screening, Randomisation and prior to administration of first dose: requiring respiratory support by High-Flow Oxygen = 30 L/min with FiO2 = 30% or Non-Invasive Mechanical Ventilation or Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation., At Screening, C-reactive protein = 50 mg/L. C-reactive protein measurement must be repeated and confirmed to be = 50 mg/L if randomisation is not done within 24 h of Screening sample collection (local laboratory testing)., PaO2/FiO2 ratio = 300 mmHg (= 40 kPa), with PaO2 from arterial blood (or arterialised capillary blood from a vasodilated ear lobe)., Treatment initiation no more than 48 h after initiation of respiratory support (High-Flow Oxygen = 30 L/min with FiO2 = 30%, Non-Invasive Mechanical Ventilation, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation)., Written informed consent obtained from patient or legally designated representative or authorisation from an independent physician*, as per local guidelines. * In emergency situations, when prior consent of the participant or their legally designated representative is not possible, enrolment of the participant may be authorised by an independent physician (NON-EU Countries) or a treating physician independent of the research team (EU Countries), as per local guidelines. The participant or the participant’s legally designated representative should be informed about the trial as soon as possible, and consent should be requested., Age = 18 years to = 85 years., Body mass index = 17.5 kg/m² and = 40 kg/m².

Exclusion Criteria

Refractory septic shock at Screening, Randomisation or prior to administration of the first dose of study drug. Participants can be enrolled if they are no longer refractory. The presence of refractory septic shock shall be determined by the investigator. As a guidance, septic shock may be judged as refractory if treatment with = 0.5 mcg/kg/min norepinephrine or equivalent (cumulative) for at least 2 h to maintain or attempt to maintain systolic blood pressure (SBP) >90 mmHg (or mean arterial pressure (MAP) >70 mmHg) after adequate fluid resuscitation is required., Not expected to survive 72 h, at Screening, Randomisation or prior to administration of first dose., Hospital-acquired or ventilator-associated pneumonia or known or suspected pneumonia due to aspiration or other physical injury or trauma or tuberculosis., Known fibrotic lung disease, bronchiectasis with = 3 exacerbations requiring antibiotic treatment during the last year or any other known severe chronic respiratory disease (e.g., chronic obstructive pulmonary disease or cystic fibrosis) requiring home oxygen/non-invasive ventilation or with known forced expiratory volume in the first second < 30%., Factors other than a pathogen suspected or confirmed to be causative for the respiratory insufficiency, e.g., clinically suspected pulmonary thromboembolism, cardiac insufficiency, including decompensated heart failure (= Class 3, New York Heart Association classification)., Active malignant disease with chemotherapy or immunomodulating cancer therapy within 30 days of screening or intended within the next 30 days or active primary lung cancer or another malignancy metastatic to the lungs or end-stage cancer., Hepatocellular injury defined by an alanine aminotransferase or aspartate aminotransferase value = 3 times the upper limit of normal (local laboratory). Known acute or chronic liver disease with Child-Pugh C., Any medical disease (acute, subacute, intermittent, or chronic) or condition that, in the opinion of the investigator(s), compromises the participant’s safety or compromises the interpretation of the results., Vasopressors, intubation, renal replacement therapy or cardiopulmonary resuscitation procedures are precluded on the basis of a patient order, next-of-kin communication or per staff decision. Clarification: The exclusion only applies when the precluded therapies or procedures result in a limitation in Standard of Care treatment escalation., Applicable in France only. Persons under court protection, persons not affiliated to a social security system, protected adults (Art. L. 1121-6, Art. L. 1121-8, Art. L. 1121-8-1)., Receiving chronic immunosuppressive therapy in clinically relevant doses (> 15 mg/day prednisolone or equivalent as maintenance treatment for > 14 days)., Known immunodeficiency disease/condition (iatrogenic or congenital), including human immunodeficiency virus infection (type 1 or 2) with CD4+ counts < 200 cells/µL, asplenia, or recurrent severe infections., Nursing and pregnant women (defined as the state after conception until the termination of gestation, screened in all women of child-bearing potential with a chorionic gonadotrophin blood test (local laboratory)., Current or recent participation in an investigational trial (within 30 days of screening, or 5 half-lives of the respective investigational compound, whichever is longer)., Systemic treatment with any complement inhibitor, e.g., eculizumab or avacopan., Known complement deficiency.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified